Why the study?
Does pegylated liposomal doxorubicin plus docetaxel improve time to progression compared with docetaxel monotherapy in women with metastatic breast cancer previously treated with anthracyclines?
Does pegylated liposomal doxorubicin plus docetaxel improve time to progression compared with docetaxel monotherapy in women with metastatic breast cancer previously treated with anthracyclines?
Adding pegylated liposomal doxorubicin to docetaxel improves time to progression without additive cardiotoxicity in advanced breast cancer patients previously treated with anthracyclines.
Supports PLD-docetaxel over docetaxel monotherapy in anthracycline-pretreated metastatic breast cancer; extends RCT evidence on efficacy and cardiac safety.
The PLD-docetaxel combination was more effective than docetaxel alone in women with metastatic breast cancer who had experienced relapse at least 1 year after prior adjuvant anthracycline therapy without an increase in cardiac toxicity, although mucocutaneous toxicity was more common.
No takes yet. Share an insight, caveat, or question.
Sparano et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: